Related Experiment Video
Updated: Aug 6, 2025

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
Published on: June 4, 2021
A Case of Argatroban Refractory Heparin Induced Thrombocytopenia and Thrombosis
Joclyn A Seiler1, Adam Khan Durrani2, Mentor Ahmeti1,3
1Department of Surgery, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND, USA.
Prophylaxis for deep vein thrombosis is a standard of care for most hospitalized patients. This is typically given in the form of chemical prophylaxis by either, unfractionated heparin or low molecular weight heparin. One complication of administration, besides bleeding, is heparin induced thrombocytopenia (HIT). Of patients receiving therapeutic anticoagulation with heparin an estimated, .5%-1% will go on to develop heparin induced thrombocytopenia.1 We will present a case of argatroban refractory HIT after a coronary artery bypass grafting resulting in a massive left ventricular thrombus and death. There is a paucity of literature on the topic of argatroban refractory HIT. When it is discussed, the persistent drop of platelets and ongoing thrombosis, despite argatroban therapy, appears to be the hallmark. The treatment being used in these rare cases is intravenous immunoglobulin. Our case sheds light on the existence of this entity and helps consolidate some literature on the topic.
Prophylaxis for deep vein thrombosis is a standard of care for most hospitalized patients. This is typically given in the form of chemical prophylaxis by either, unfractionated heparin or low molecular weight heparin. One complication of administration, besides bleeding, is heparin induced thrombocytopenia (HIT). Of patients receiving therapeutic anticoagulation with heparin an estimated, .5%-1% will go on to develop heparin induced thrombocytopenia.1 We will present a case of argatroban refractory HIT after a coronary artery bypass grafting resulting in a massive left ventricular thrombus and death. There is a paucity of literature on the topic of argatroban refractory HIT. When it is discussed, the persistent drop of platelets and ongoing thrombosis, despite argatroban therapy, appears to be the hallmark. The treatment being used in these rare cases is intravenous immunoglobulin. Our case sheds light on the existence of this entity and helps consolidate some literature on the topic.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

